SYRE
Spyre Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +2 | 602.45K | $53.61M | +2 | n/a |
| Q2 2026 | 99 | +22 | 55.44M | $4.93B | +25 | −3 |
| Q1 2026 | 80 | +10 | 41.69M | $2.10B | +12 | −2 |
| Q4 2025 | 69 | +2 | 41.90M | $1.37B | +2 | n/a |
| Q3 2025 | 13 | -1 | 23.21M | $388.94M | +1 | −2 |
| Q2 2025 | 11 | 0 | 22.40M | $335.38M | +2 | −2 |
| Q1 2025 | 8 | -2 | 6.01M | $96.96M | n/a | −2 |
| Q4 2024 | 10 | +1 | 7.67M | $178.64M | +2 | −1 |
| Q3 2024 | 8 | 0 | 4.78M | $140.58M | +1 | −1 |
| Q2 2024 | 8 | n/a | 3.96M | $93.00M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 1.15M | n/a | $27.09M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 795.95K | n/a | $18.71M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 3 | Geode Capital Management ✦ (passive) | 765.83K | n/a | $18.01M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 707.59K | n/a | $16.64M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 307.98K | n/a | $7.24M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Soros Fund Management ✦ | 145.00K | n/a | $3.41M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 70.84K | n/a | $1.67M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 9.84K | n/a | $231,385 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 197 holders, 82.12M shares, $4.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 229 sh · $21,428
Officer · 1.50K sh · $135,405
Officer · 3.07K sh · $285,449
Officer · 600 sh · $53,442
Officer · 2.10K sh · $193,032
Officer · 17.50K sh · $1.57M
Officer · 18.23K sh · $1.63M
Officer · 400 sh · $36,000
Officer · 16.55K sh · $1.44M
Officer · 900 sh · $77,625
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
9.2% of class · View original SEC filing ↗
9.2% of class · View original SEC filing ↗